Pacific Biosciences (PACB) Gets a Hold from Piper Sandler
In a report released today, David Westenberg from Piper Sandler reiterated a Hold rating on Pacific Biosciences (PACB – Research Report), with ...
The Goldman Sachs Group Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.50
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) had its price target dropped by research analysts at The ...
Pacific Biosciences of California Sees Unusually High Options Volume (NASDAQ:PACB)
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) was the target of unusually large options trading activity on Tuesday. Investors acquired 31,944 call options on the stock. This ...
Pacific Biosciences of California Full Year 2024 Earnings: EPS Beats Expectations
Full Year 2024 Results Key Financial Results Revenue: US$154.0m ...
Zacks.com on MSN7d
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 13, 2025 Pacific Biosciences of California, Inc. beats earnings expectations.
Morgan Stanley Sticks to Its Hold Rating for Pacific Biosciences (PACB)
Morgan Stanley analyst Tejas Savant maintained a Hold rating on Pacific Biosciences (PACB – Research Report) today and set a price target of ...